Phase II Study of RAD001 Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma

被引：0
|
作者：
Kim, D. [1 ]
Shin, S. [2 ]
Kang, J. [3 ]
Cho, B. [4 ]
Kim, H. [5 ]
Jung, J. [6 ]
Park, K. [7 ]
Kwon, J. [8 ]
Hang, J. [9 ]
Bang, Y. [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Kosin Univ, Gospel Hosp, Dept Internal Med, Pusan, South Korea
[3] Catholic Univ, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
[4] Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[5] Vet Hosp, Dept Internal Med, Seoul, South Korea
[6] Pusan Natl Univ Hosp, Dept Internal Med, Pusan, South Korea
[7] Keimyung Univ, Dept Internal Med, Dongsan Med Ctr, Taegu, South Korea
[8] Hallym Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
[9] Natl Canc Ctr, Ctr Lung Canc, Ilsan, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72144-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S544 / S544
页数：1
相关论文
共 50 条
  • [31] Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma
    Rosenberg, J. E.
    Weinberg, V. K.
    Claros, C.
    Ryan, C.
    Lin, A. M.
    Fong, L.
    Brocks, D.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
    Tarhini, Ahmad
    Kotsakis, Athanasios
    Gooding, William
    Shuai, Yongli
    Petro, Daniel
    Friedland, David
    Belani, Chandra P.
    Dacic, Sanja
    Argiris, Athanassios
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5900 - 5907
  • [33] Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial
    Hoover, Andrew C.
    Milhem, Mohammed M.
    Anderson, Carryn M.
    Sun, Wenqing
    Smith, Brian J.
    Hoffman, Henry T.
    Buatti, John M.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (05): : 722 - 726
  • [34] Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
    Lau, David K.
    Tay, Rebecca Y.
    Yeung, Yvonne H.
    Chionh, Fiona
    Mooi, Jennifer
    Murone, Carmel
    Skrinos, Effie
    Price, Timothy J.
    Mariadason, John M.
    Tebbutt, Niall C.
    BRITISH JOURNAL OF CANCER, 2018, 118 (07) : 966 - 971
  • [35] Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
    David K. Lau
    Rebecca Y. Tay
    Yvonne H. Yeung
    Fiona Chionh
    Jennifer Mooi
    Carmel Murone
    Effie Skrinos
    Timothy J. Price
    John M. Mariadason
    Niall C. Tebbutt
    British Journal of Cancer, 2018, 118 : 966 - 971
  • [36] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [37] Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET)
    Yao, J. C.
    Phan, A.
    Chang, D. Z.
    Wolff, R. A.
    Jacobs, C.
    Mares, J. E.
    Gupta, S.
    Meric-Bernstam, F.
    Rashid, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
    Kotsakis, A. P.
    Tarhini, A.
    Petro, D.
    Flaugh, R.
    Vallabhaneni, G.
    Belani, C. P.
    Friedland, D.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)
    Owonikoko, T. K.
    Stoller, R. G.
    Petro, D.
    Flaugh, R.
    Hershberger, P. A.
    Belani, C. P.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345